Skip to content
7 stages · illustrated process map

VLP Production Platform — R&D Workflow

How a modular 4-protein virus-like-particle candidate is screened end to end: design & cloning, dual-vector rescue and amplification, titration, co-infection & self-assembly, clarification, and QC. Only the antigen changes between the 100+ constructs — everything downstream is a fixed pipeline.

Stages
0–6
Variable
the antigen
Make-or-break
assembly

Primer

What is a virus-like particle?

A virus-like particle is a virus with the dangerous part removed. Its structural proteins self-assemble into the same shell geometry a real virus wears — but there is no genome inside. Nothing to replicate, nothing to integrate into a host chromosome, nothing to revert to a virulent form. To a B-cell it looks like an incoming pathogen; to the patient it is inert protein.

That geometry is the whole point. The immune system evolved to react hard to dense, repetitive surfaces — a real virion presents dozens to hundreds of identical spikes in a rigid lattice, which cross-links B-cell receptors and trips the complement cascade far more efficiently than a lone protein drifting past. A VLP copies that lattice, so it raises high neutralizing-antibody titers at a low dose, often without a heavy adjuvant.

VLPs sit between the two older vaccine styles. Live-attenuated virus is potent but carries a real genome and real risk; a soluble subunit protein is safe but weakly immunogenic. A VLP keeps most of the potency of the first with the safety of the second — which is why the Hepatitis B and HPV vaccines given to hundreds of millions of people are, structurally, VLPs.

What is new is treating the shell as a reusable platform: a fixed, validated backbone that carries a swappable antigen. That is exactly the logic this map traces — only the antigen changes across the 100+ constructs, and the entire downstream process is one pipeline. Build the process once; screen candidates for years.

What changesWhat changes between the 100+ screened constructs? Only the antigen (Stage 0). The backbone, the two vectors, the process and the equipment are a fixed, repeatable pipeline.
Make-or-breakMake-or-break: Stage 3 (get the 1:1 MOI right) → Stage 4 (do the 4 fused proteins actually co-assemble).
Rows
Process steps
  1. Design the antigen–backbone fusion in silico (linker, dual promoters polh / p10).
  2. Synthesise / assemble the fused gene cassettes.
  3. Clone the cassettes into transfer Plasmid A (genes 1 & 2) and Plasmid B (genes 3 & 4).
  4. Transform E. coli, pick clones, miniprep and sequence-verify (Sanger / NGS).
  1. Co-transfect host-cell monolayers in static multi-well plates: Plasmid A + linearised viral DNA in one set of wells, Plasmid B + viral DNA in another (never mixed).
  2. Homologous recombination inside the cells packages each plasmid's genes into recombinant Baculovirus Vector A / Vector B.
  3. Harvest un-amplified P0 seed per well (~100–200 µL) — separate stocks for Vector A and Vector B.
  1. Inoculate host-cell suspension in shaking bottles / T-flasks with P0 seed — a SEPARATE culture for Vector A and for Vector B (kept apart).
  2. Maintain continuous agitation (orbital shaking / rocking) to maximise aeration and viability.
  3. Perform daily manual or automated sampling to measure cell viability.
  4. Harvest at ~60% live/dead ratio. Execute an optional P2 passage if larger volumes are needed.
  1. Prepare serial dilutions of Vector A and Vector B working stocks across micro-plates.
  2. Inoculate reporter cells and incubate.
  3. Measure signal intensity across dilution steps to calculate infectious viral titers (PFU/mL).
  1. Co-infect host-cell suspension in large vessels (shake flasks up to 3 L) with Vectors A & B at the calibrated MOI.
  2. Incubate under continuous shaking / rocking.
  3. Draw daily samples to track host-cell mortality.
  4. Terminate culture at the target viability drop — signalling maximum VLP expression and secretion.
  1. Centrifuge the bulk harvest to pellet dead insect cells and heavy debris.
  2. Collect the VLP-containing supernatant and discard the cell pellet.
  3. Process the supernatant through TFF cassettes to concentrate VLPs and remove low-MW contaminants.
  1. Run SDS-PAGE and Western blotting to confirm presence and weights of all 4 structural proteins.
  2. Prepare negative-stain TEM grids and inspect particle size and spherical structure.
  3. Test antigen-binding affinity by SPR or ELISA.
  4. Perform safety and endotoxin screening prior to in-vivo mouse immunogenicity studies.
Key bottleneck
!Bespoke per construct — the design-heavy step; each antigen is a fresh clone + sequence check.
!Contamination risk from frequent plate openings; the static rescue is slow (4–14 days).
!Daily manual sampling is the labour bottleneck; A and B must stay separate and uncontaminated.
The exact 1:1 A:B MOI must be right — a wrong ratio starves the assembly of one of the four proteins.
Make-or-break: many antigens won't fold / co-assemble. Construct attrition is highest here.
!VLP losses during centrifugation / TFF — gentle handling to keep particles intact.
!Proving correct 4-protein stoichiometry + intact assembly; slow, hands-on (6–8 hrs).
Process & visualization
Stage 0 — Design & cloning

The molecular-biology team designs the antigen fusion and clones it into the two transfer plasmids — this is the ONE step that changes between experiments; everything after it is a fixed pipeline.

scene s1

Co-transfect the two plasmids SEPARATELY (one set of wells each) to rescue recombinant baculovirus Vectors A and B — kept apart from the very start.

scene s2

Propagate Vector A and Vector B in TWO separate cultures (never mixed) to build high-titer working stocks — they are only combined later, at Stage 4 co-infection.

scene s3

Quantify infectious titers of A and B to set an exact 1:1 co-infection ratio — equal delivery of all 4 components.

scene s4

Co-infect with A & B; ribosomes translate all 4 fused proteins concurrently, which self-assemble into antigen-displaying 3D VLPs.

scene s5

Separate assembled VLPs from cells and debris — centrifuge out the cell pellet, then concentrate by TFF.

scene s6

Confirm all 4 proteins are present in ratio and correctly assembled into intact, antigen-displaying particles.

Equipment & operator process
Stage 0 — operator (cloning)

Molecular biologist clones + sequence-verifies Plasmids A & B at the DNA bench.

scene op s1

Operator co-transfects 6-well plates inside the BSC · 2–3 hrs active.

scene op s2

Operator seeds shake bottles into the shaker + daily viability checks.

scene op s3

Operator lays out serial dilutions + reads the fluorometer plate.

scene op s4

Operator co-infects 3 L flasks + samples daily · 3–4 hrs active.

scene op s5

Operator runs the floor centrifuge, then TFF concentration.

scene op s6

Operator runs gels/blots, prepares TEM grids, reads SPR.

Hardware / equipment
  • Thermocycler (PCR)
    Thermocycler (PCR)
    Thermal cycler — runs the PCR / assembly reactions and colony-PCR checks during cloning.
  • DNA sequencer
    DNA sequencer
    DNA sequencer — Sanger / NGS confirmation that each plasmid carries the correct fused insert.
  • Multichannel pipette
    Multichannel pipette
    Multichannel pipette — parallel liquid handling across plate rows (dilutions, transfers, plating).
  • Conical tubes
    Conical tubes
    15/50 mL conical tubes — collect and store P0 seed supernatant, media and reagents.

Consumables: Transfer-plasmid backbones A & B · synthetic antigen DNA · assembly / restriction mix · competent E. coli · miniprep + sequencing kits

  • Biosafety Cabinet (BSC Class II)
    BSC Class II
    Class II biosafety cabinet — HEPA-filtered sterile workspace that protects both the cultures and the operator during open handling.
  • Static CO2 incubator
    Static incubator
    Static CO₂ incubator — holds sealed culture plates at controlled temperature/CO₂ through the multi-day static rescue.
  • 6-well (M6) culture plate
    6-well (M6) plates
    6-well (M6) static plates — the vessel for co-transfecting host-cell monolayers at screening scale.
  • Conical tubes
    Conical tubes
    15/50 mL conical tubes — collect and store P0 seed supernatant, media and reagents.
  • Multichannel pipette
    Multichannel pipette
    Multichannel pipette — parallel liquid handling across plate rows (dilutions, transfers, plating).

Consumables: M6 / M24 static plates · 15/50 mL conical tubes · sterile filter units · pipette tips

  • Shaker / rocker incubator
    Shaker / rocker incubator
    Orbital shaker / rocker incubator — continuous agitation to aerate suspension cultures and keep cells viable.
  • Biosafety Cabinet (BSC Class II)
    BSC Class II
    Class II biosafety cabinet — HEPA-filtered sterile workspace that protects both the cultures and the operator during open handling.
  • Automated cell counter
    Automated cell counter
    Automated cell counter — reads live/dead viability (Trypan Blue) from a microfluidic slide.
  • Microfluidic counting slide
    Microfluidic counting slide
    Microfluidic counting slide — single-use cassette that feeds one sample to the cell counter.
  • Small shaking bottle
    Small shaking bottles
    Small shaking bottle — vented vessel for amplifying viral stocks in agitated suspension.

Consumables: Shaking bottles / T-flasks · Microfluidic counting slides · Trypan Blue reagent · Sampling vials · pipette tips

  • Microplate fluorometer
    Microplate fluorometer
    Microplate fluorometer / reader — measures reporter-cell fluorescence to compute infectious titer.
  • Biosafety Cabinet (BSC Class II)
    BSC Class II
    Class II biosafety cabinet — HEPA-filtered sterile workspace that protects both the cultures and the operator during open handling.
  • Multichannel pipette
    Multichannel pipette
    Multichannel pipette — parallel liquid handling across plate rows (dilutions, transfers, plating).
  • Deep-well dilution plate
    Deep-well dilution plates
    Deep-well dilution plate — holds the serial-dilution series for titration.

Consumables: 96-well microplates · deep-well dilution plates · micropipette tips · optical plate seals

  • Shaker / rocker incubator
    Large shaking incubator
    Orbital shaker / rocker incubator — continuous agitation to aerate suspension cultures and keep cells viable.
  • Biosafety Cabinet (BSC Class II)
    BSC Class II
    Class II biosafety cabinet — HEPA-filtered sterile workspace that protects both the cultures and the operator during open handling.
  • Automated cell counter
    Automated cell counter
    Automated cell counter — reads live/dead viability (Trypan Blue) from a microfluidic slide.
  • 1–3 L shake flask
    1–3 L shake flasks
    1–3 L shake flask — the largest screening vessel, for the co-infection / VLP-assembly run.

Consumables: 1–3 L shake flasks / bottles · sampling syringes / vials · microfluidic counting slides · Trypan Blue reagent

  • High-capacity floor centrifuge
    High-capacity floor centrifuge
    High-capacity floor centrifuge — pellets dead cells and heavy debris from the bulk harvest.
  • TFF filtration skid
    TFF filtration skid + cassettes
    TFF filtration skid — tangential-flow cassettes concentrate the VLPs and wash out low-MW contaminants.
  • Peristaltic pump
    Peristaltic pump
    Peristaltic pump — drives harvest/buffer through the TFF cassettes at a controlled, contamination-free flow.
  • Collection bottle
    Collection bottles
    Collection bottle — sterile vessel for the clarified, concentrated VLP solution.

Consumables: Centrifuge bottles (500 mL–1 L) · TFF cassettes (100–300 kDa MWCO) · sanitary silicone tubing · collection bottles

  • Low-voltage TEM (Cryo-EM)
    Low-voltage TEM (Cryo-EM)
    Low-voltage TEM (Cryo-EM) — direct imaging of particle size and spherical structure (20–200 nm).
  • SDS-PAGE gel tank
    SDS-PAGE tank
    SDS-PAGE gel tank — separates the 4 structural proteins by molecular weight.
  • Western blot transfer apparatus
    Western blot apparatus
    Western blot transfer apparatus — transfers separated proteins to membrane for antibody detection.
  • Gel / blot imaging system
    Imaging system
    Gel / blot imaging system — captures chemiluminescent band images for QC records.
  • SPR / ELISA reader
    SPR / ELISA reader
    SPR / ELISA reader — measures the antigen-binding affinity of the displayed surface antigens.

Consumables: Polyacrylamide gels · PVDF membranes · carbon-coated TEM grids · chemiluminescent substrates · micro-tubes · filter paper

Time & effort
Duration1–3 weeks
People👤 1 person
Hours/stepdesign-heavy
Duration4–14 days
People👤 1 person
Hours/step2–3 hrs
Duration4–7 days / passage
People👤 1 person
Hours/step3–5 hrs
Duration24–48 hrs
People👤 1 person
Hours/step2–3 hrs
Duration3–7 days
People👤 1 person
Hours/step3–4 hrs
Duration4–6 hrs
People👤 1 person
Hours/step3–4 hrs
Duration1–2 days
People👤 1 person
Hours/step6–8 hrs

Illustrations generated in the A4BEE graphics style from labelled objects; every capability and step traces to the process definition. A modular 4-protein VLP structural backbone presents target antigens (e.g. HER2, GD2 mimetics, multi-epitope chains). Antigens are genetically fused onto backbone DNA — the cell synthesises pre-fused chimeric proteins that self-assemble; it never builds an empty shell. Four structural genes are split across two recombinant baculovirus vectors — Vector A (Backbone Proteins 1 & 2), Vector B (Backbone Proteins 3 & 4). Screening-scale throughput (96-/24-well → 6-well → shaking bottles → 3 L flasks); no industrial bioreactors at this stage.

Why this platform

What VLPs beat, and how

Beats soluble subunits on immunogenicity

A lone protein has no repetitive structure, so it needs high doses and strong adjuvants to protect. The VLP's multivalent geometry cross-links B-cell receptors and activates complement like a real virion — higher neutralizing titers, longer-lived immunity and stronger memory-B recall, at a lower antigen dose.

Safer than live-attenuated and viral vectors

No viral genome means no reversion to virulence, no genomic integration and no infectious risk — and it stays usable in immunocompromised patients. Unlike adenoviral vectors, there is no anti-vector immunity to blunt the boost on repeat dosing.

Ships without an ultra-cold chain

mRNA-LNP prototypes fast but lives at −80 to −20 °C. VLPs are physically and thermally sturdier — frequently stable at 2–8 °C, and lyophilizable toward ambient. That is the difference between reaching a clinic in a capital city and reaching one that isn't.

One backbone, many antigens

Insert a foreign epitope into a surface loop (chimeric and mosaic particles) or bolt it on with SpyTag/SpyCatcher, and a generic shell becomes a display platform. Viral, bacterial, parasitic, toxin and oncology targets attach to the same pre-manufactured backbone — platform flexibility with one standardized downstream process. This is the "only the antigen changes" thesis of the map.

History

Forty years of VLP vaccines

  1. 1986
    The first VLP vaccine — and the first recombinant vaccine

    Hepatitis B surface antigen, expressed in yeast, self-assembles into empty particles (Recombivax HB, Engerix-B). The proof that a genome-free protein shell can protect at population scale.

  2. 2006
    Gardasil, then Cervarix — VLPs against cancer

    HPV L1 capsid proteins assembled into VLPs become the first vaccines to prevent a human cancer, and the proof the platform scales to a global product.

  3. 2011
    Hecolin — the only Hepatitis E vaccine

    Xiamen Innovax produces a Hep E VLP in E. coli — still the world's only licensed vaccine for the disease, and a demonstration that VLPs do not need mammalian or insect cells.

  4. 2012
    SpyTag / SpyCatcher — protein superglue

    The Howarth lab in Oxford engineers a peptide-protein pair that forms a spontaneous covalent bond, letting an antigen snap onto a pre-made backbone. The technical basis for modern plug-and-display.

  5. 2021
    RTS,S / Mosquirix — the first malaria vaccine

    WHO recommends a scaffold VLP that hangs a P. falciparum antigen on the Hep B surface protein — a chimeric particle carrying a target its backbone never came from.

  6. 2023–24
    Designed particles get hot; economics still bite

    AstraZeneca acquires Icosavax and its computationally-designed two-component VLPs (RSV + hMPV) for over $1B, while Medicago's plant-made COVID VLP is approved and then wound down — the science is compelling, the manufacturing economics are not automatic.

Landscape

Who is building in this space

Merck

Pharma

Gardasil 9 (HPV) and Recombivax HB (Hep B) — the highest-volume proof that VLP vaccines manufacture and sell at global scale.

GSK

Pharma

Engerix-B, Cervarix (HPV) and Mosquirix/RTS,S — the scaffold-VLP malaria vaccine that carries a parasite antigen on the Hep B surface protein.

Novavax

Biotech

Recombinant protein-nanoparticle vaccines (COVID, flu) paired with its Matrix-M adjuvant — nanoparticle-adjacent rather than a classic VLP, but the same display-on-a-particle playbook.

SpyBiotech

Platform · Oxford spinout

Commercialising SpyTag/SpyCatcher plug-and-display; CMV and malaria candidates built on a snap-on backbone.

Vaxican

Startup · Poland

A Polish startup developing virus-like-particle vaccines — an emerging European entrant building on the VLP-display approach.

Icosavax (AstraZeneca)

Biotech

Computationally-designed two-component self-assembling VLPs; the RSV + hMPV combo (IVX-A12) drove a >$1B acquisition in 2024.

VBI Vaccines

Biotech

Enveloped VLPs (eVLP) that add a lipid membrane for membrane-bound antigens; PreHevbrio (3-antigen Hep B) and a CMV programme.

Xiamen Innovax / Wantai

Pharma · China

Hecolin — the only Hepatitis E vaccine anywhere — plus Cecolin (HPV), both E. coli-produced VLPs.

Serum Institute of India

Pharma

Cervavac, a low-cost HPV VLP engineered for high-volume, low-margin markets.

Medicago

Biotech · wound down 2023

Plant-made VLPs; Covifenz was the first plant-produced COVID vaccine approved (Canada) before the programme closed — a reminder that platform novelty doesn't guarantee economics.

A4BEE's own research, compiled from public information. Company and product names are trademarks of their respective owners and are used here for identification only; this map is not affiliated with or endorsed by any of them.

What's inside

  • A plain-language primer on what a VLP is and why the immune system reacts to it
  • 7 stages (0–6) as columns — Design & Cloning through Structural QC — with two illustrated hero rows each (biology + operator process)
  • Numbered process steps, the key bottleneck per stage, a labelled+described hardware row, and time & effort
  • Why VLPs beat soluble subunits, live-attenuated virus, viral vectors and mRNA — and where they don't
  • A 40-year history of VLP vaccines and a map of the companies and startups building in the space

Best used for

  • Onboarding a team to a screening-scale VLP platform
  • Reviewing where the throughput bottlenecks and scientific make-or-break points are
  • Explaining the dual-vector logic (separate A & B until co-infection) to stakeholders

Questions about this resource?

Want it in a different format, need the methodology behind a number, or wondering how it applies to your programme? Ask a practitioner — a straight answer, usually within one business day.